Diabetes technology & therapeutics · 2026
Automated Insulin Delivery System Initiation Safely Improves Glycemic Outcomes in Older Adults with Type 1 Diabetes.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Quirós Carmen, Granados Montserrat, Picón María J, Nattero-Chávez Lía, Aguilera-Hurtado Eva, Vallejo-Mora María Del Rosario, Beato-Víbora Pilar, Azriel-Mira Sharona, Moreno-Fernández Jesús, Simó-Servat Olga, Zavala-Arauco Roxana, Díaz-Soto Gonzalo, Alonso-Carril Nuria, Martínez-Brocca María A, Diaz-Trastoy Olaia, Guerrero Laura, Andújar Paula, Duran-Martínez María, Márquez Rosa, Piedra-León María, Climent Elisenda, Chico Ana
Аннотация
OBJECTIVE: To evaluate real-world glycemic outcomes, safety, treatment satisfaction, cognition, and frailty in older adults with type 1 diabetes (T1D) using advanced hybrid closed-loop (aHCL), and to compare them with those of matched older adults treated with multiple daily injections (MDIs).
RESEARCH DESIGN AND METHODS: Multicenter observational study including 100 adults with T1D from 19 Spanish hospitals who initiated aHCL at ≥65 years and 100 age- and sex-matched MDI users. Glycemic outcomes before aHCL initiation were compared with the final follow-up. Final glycemic outcomes were also compared between the aHCL and MDI groups. Cognitive function and frailty were assessed using the Montreal Cognitive Assessment and FRAIL scales.
RESULTS: Mean age was 71.2 ± 4.4 years. In aHCL users, time in range (TIR 70-180 mg/dL) increased from 65.3% ± 15.0% before aHCL initiation to 78.6% ± 10.5% at the final follow-up (P < 0.001), and HbA1c decreased from 7.56% ± 0.97% to 7.01% ± 0.59% (59.1 ± 10.6 mmol/mol to 53.1 ± 6.4 mmol/mol) (P < 0.001). At the final follow-up, aHCL users had a higher TIR than matched MDI users (78.6% ± 10.5% vs. 63.0% ± 18.1%; P < 0.001) and lower HbA1c (7.01% ± 0.59% vs. 7.65% ± 0.98%; 53.1 ± 6.4 mmol/mol to 59.9 ± 10.7 mmol/mol; P < 0.001). Severe hypoglycemia decreased from 28.0 to 1.6 events per 100 patient-years after aHCL initiation. A total of 60% of aHCL users had mild-to-moderate cognitive impairment, yet the final TIR was similar across cognitive strata within the aHCL group.
CONCLUSIONS: In older adults with T1D, real-world aHCL initiation was associated with improved glycemic outcomes and better glycemic outcomes than in matched MDI users in a cohort with substantial cognitive vulnerability. These findings support the effectiveness of aHCL therapy in routine geriatric diabetes care.
RESEARCH DESIGN AND METHODS: Multicenter observational study including 100 adults with T1D from 19 Spanish hospitals who initiated aHCL at ≥65 years and 100 age- and sex-matched MDI users. Glycemic outcomes before aHCL initiation were compared with the final follow-up. Final glycemic outcomes were also compared between the aHCL and MDI groups. Cognitive function and frailty were assessed using the Montreal Cognitive Assessment and FRAIL scales.
RESULTS: Mean age was 71.2 ± 4.4 years. In aHCL users, time in range (TIR 70-180 mg/dL) increased from 65.3% ± 15.0% before aHCL initiation to 78.6% ± 10.5% at the final follow-up (P < 0.001), and HbA1c decreased from 7.56% ± 0.97% to 7.01% ± 0.59% (59.1 ± 10.6 mmol/mol to 53.1 ± 6.4 mmol/mol) (P < 0.001). At the final follow-up, aHCL users had a higher TIR than matched MDI users (78.6% ± 10.5% vs. 63.0% ± 18.1%; P < 0.001) and lower HbA1c (7.01% ± 0.59% vs. 7.65% ± 0.98%; 53.1 ± 6.4 mmol/mol to 59.9 ± 10.7 mmol/mol; P < 0.001). Severe hypoglycemia decreased from 28.0 to 1.6 events per 100 patient-years after aHCL initiation. A total of 60% of aHCL users had mild-to-moderate cognitive impairment, yet the final TIR was similar across cognitive strata within the aHCL group.
CONCLUSIONS: In older adults with T1D, real-world aHCL initiation was associated with improved glycemic outcomes and better glycemic outcomes than in matched MDI users in a cohort with substantial cognitive vulnerability. These findings support the effectiveness of aHCL therapy in routine geriatric diabetes care.